# A Study to Evaluate SAGE-217 in Participants With Parkinson's Disease

> **NCT03000569** · PHASE2 · COMPLETED · sponsor: **Biogen** · enrollment: 29 (actual)

## Conditions studied

- Parkinson Disease

## Interventions

- **DRUG:** SAGE-217
- **DRUG:** Levodopa
- **DRUG:** Antiparkinsonian Agent(s)

## Key facts

- **NCT ID:** NCT03000569
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-11-30
- **Primary completion:** 2017-09-11
- **Final completion:** 2017-09-11
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2023-11-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03000569

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03000569, "A Study to Evaluate SAGE-217 in Participants With Parkinson's Disease". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03000569. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*